ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
02 Ottobre 2024 - 2:00PM
Business Wire
Talem Therapeutics' Antibody Asset to be
Evaluated for Bispecific Development Against Solid Tumors
ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”)
(NASDAQ: IPA), an AI-driven biotherapeutic research and technology
company, and Biotheus Inc. (Biotheus), a clinical-stage biotech
company dedicated to the discovery and development of biologics for
oncology and inflammatory diseases, jointly announce that the two
parties have entered into a Material Transfer and Evaluation
Agreement (MTEA) pertaining to a Talem therapeutic antibody asset
for the development of a bispecific therapy against solid tumors.
Under this MTEA, Biotheus will obtain the rights to further
evaluate the suitability of Talem’s Artificial Intelligence
(AI)-enhanced TATX-20 lead candidate for the development of novel
bispecific antibodies for the treatment of hypoxic solid
tumors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20241002122615/en/
Under this agreement, Biotheus will receive a specialized
antibody asset from Talem Therapeutics, a subsidiary of
ImmunoPrecise Antibodies. Biotheus plans to use this asset in
conjunction with its own proprietary technology and binders to
develop a new class of cancer-fighting drugs. These innovative
therapeutics, known as bispecific antibodies, are designed to
simultaneously target two different targets on tumors, specifically
those found in oxygen-deprived environments. This approach could
potentially lead to breakthrough therapies that address the complex
challenges of treating cancer, particularly in difficult-to-target
tumor environments. The ultimate goal is to identify the most
promising molecule for advancement into clinical trials,
potentially accelerating the development of novel cancer
treatments.
"We are happy to enter into a collaboration with ImmunoPrecise
Antibodies, a leading AI-driven biotech with powerful multi-omics
modelling expertise." stated Xiaolin Liu, Co-founder, Chairman, and
CEO of Biotheus. “Biotheus' broad expertise in antibody discovery
and development is powered by our fully integrated capabilities. By
virtue of the AI-informed molecules spawned by ImmunoPrecise's
platform, we aim to develop novel bispecific antibodies with
first-in-class potential and bring forth breakthrough therapies to
cancer patients in the world."
Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies, stated:
"We're excited to transfer our AI-enhanced therapeutic antibody
asset to Biotheus for bispecific molecule development. This
strategic move leverages our cutting-edge technology in antibody
discovery and Biotheus' expertise in bispecific engineering. Our
collaboration aims to accelerate the creation of innovative cancer
treatments, potentially leading to groundbreaking clinical
outcomes. This agreement not only demonstrates the value of our
AI-enhanced assets but also sets the stage for a long-term,
mutually beneficial partnership that could transform the landscape
of cancer therapeutics. We anticipate this collaboration will drive
significant value for both companies and, most importantly, for
patients in need of advanced treatment options."
The transfer of this therapeutic asset to Biotheus aims to
accelerate the development of targeted therapies that could
potentially improve outcomes for patients with solid tumors.
Following the transfer, Biotheus will evaluate the TATX-20 lead
candidate. If the evaluation proves successful, Biotheus intends to
further develop the bispecific molecules, with the objective of
creating a clinically successful product that addresses the
challenges associated with treating hypoxic solid tumors resistant
to current therapies.
About Biotheus
Biotheus Inc. is a leading biopharmaceutical company
headquartered in Zhuhai, China, dedicated to discovering and
developing innovative therapies for oncology and immunology
diseases. Biotheus is focused on creating cutting-edge bispecific
antibodies and other biologics to target challenging tumor types
and improve patient outcomes. Since its inception, Biotheus has
established several innovative platforms for antibody discovery.
With an experienced development team, Biotheus has built a robust
pipeline of ten programs at various stages of clinical development.
For more information, visit www.biotheus.com.
About Talem Therapeutics LLC
Talem Therapeutics LLC, a subsidiary of ImmunoPrecise Antibodies
Ltd., specializes in the discovery and development of AI-driven,
next-generation antibodies with the primary goal of out-licensing
them to pharmaceutical partners. Talem focuses on creating
innovative therapeutic biologics up to the preclinical stage,
leveraging advanced platforms to accelerate antibody development
for oncology and other therapeutic areas. The company aims to
streamline the path to the clinic for its partners by providing
high-quality antibody assets ready for further development and
clinical testing. For more information, visit
www.talemtherapeutics.com.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company
that leverages multi-omics modeling and complex artificial
intelligence through a series proprietary and patented
technologies. The Company owns an integrated end-to-end suite of
capabilities to support the development of therapeutic antibodies
and are known for solving very complex industry challenges. IPA has
several subsidiaries in North America and Europe including entities
such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise
Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V.
(collectively, the “IPA Family”).
Forward-Looking Statement
This press release contains forward-looking statements within
the meaning of applicable United States securities laws and
Canadian securities laws. Forward-looking statements are often
identified by the use of words such as “expects” “estimates”,
“intends”, “anticipates” or “believes”, or variations of such words
and phrases or state that certain actions, events or results “may”,
“would”, “might” or “will” be taken, occur or be achieved.
Forward–looking statements include, but are not limited to,
statements regarding bispecific molecule development and the
development of a bispecific therapy against solid tumors. Although
the Company believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control,
including risks and uncertainties related to market and other
conditions and the impact of general economic, industry or
political conditions in the United States, Canada or
internationally. You should also consult our quarterly and annual
filings with the Canadian and U.S. securities commissions for
additional information on risks and uncertainties. These
forward–looking statements speak only as of the date of this press
release and the Company undertakes no obligation to revise or
update any forward–looking statements for any reason, even if new
information becomes available in the future.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, as discussed in the Company’s
Annual Report on Form 20-F for the year ended April 30, 2024 (which
may be viewed on the Company’s SEDAR+ profile at www.sedar.ca and
EDGAR profile at www.sec.gov/edgar). Should one or more of these
risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. Accordingly, readers should not
place undue reliance on forward-looking statements contained in
this news release. The forward-looking statements contained in this
news release are made as of the date of this release and,
accordingly, are subject to change after such date. The Company
does not assume any obligation to update or revise any
forward-looking statements, whether written or oral, that may be
made from time to time by us or on our behalf, except as required
by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241002122615/en/
Investor Relations Contact Kirsten Beduya Quantum Media
Group, LLC kirsten@quantum-corp.com
Grafico Azioni ImmunoPrecise Antibodies (NASDAQ:IPA)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni ImmunoPrecise Antibodies (NASDAQ:IPA)
Storico
Da Gen 2024 a Gen 2025
